TABLE 2.
Group assignments for AGMs that were boosted ∼6 months following priming (experiment 2)
| Animal | Sexa | Priming RSV | Boosting virus | Pre-boosting serum RSV-neutralizing titer (log2 PRNT)b | Post-boosting serum RSV-neutralizing titer (log2 PRNT)c |
|---|---|---|---|---|---|
| 8926 | M | D46/NS2/N/ΔM2-2-HindIII | RSV 276 | 7.1 | 11.4 |
| 8983 | M | 6120/ΔNS2/1030s | RSV 276 | 8 | 11.4 |
| 8974 | F | 6120/F1BBG2/ΔNS1 | RSV 276 | 6.9 | 13.3 |
| 8951 | M | 6120/ΔNS1 | RSV 276 | 3.3 | 12 |
| 8960 | F | 6120/ΔNS1 | RSV 276 | 5.2 | 13.3 |
| 8918 | F | RSV 276 | RSV 276 | 5.7 | 12.3 |
| 8938 | F | D46/NS2/N/ΔM2-2-HindIII | DS-Cav1 | 6.7 | 14.8 |
| 8911 | M | D46/NS2/N/ΔM2-2-HindIII | DS-Cav1 | 4.3 | 16.2 |
| 8928 | F | 6120/ΔNS2/1030s | DS-Cav1 | 7.5 | 13.4 |
| 8994 | M | 6120/F1BBG2/ΔNS1 | DS-Cav1 | 4.5 | 14.3 |
| 8966 | M | 6120/F1BBG2/ΔNS1 | DS-Cav1 | 5.1 | 16.1 |
| 8992 | F | 6120/ΔNS1 | DS-Cav1 | 6.6 | 14.5 |
| 8913 | M | RSV 276 | DS-Cav1 | 7.3 | 13.6 |
| 9041 | F | D46/NS2/N/ΔM2-2-HindIII | DS-Cav1/B3TMCT | 7.1 | 14.9 |
| 9045 | M | 6120/ΔNS2/1030s | DS-Cav1/B3TMCT | 8.5 | 14.1 |
| 8940 | F | 6120/ΔNS2/1030s | DS-Cav1/B3TMCT | 6.7 | 12.9 |
| 8922 | F | 6120/F1BBG2/ΔNS1 | DS-Cav1/B3TMCT | 5.1 | 22.3 |
| 8904 | M | 6120/ΔNS1 | DS-Cav1/B3TMCT | 7.1 | 15.2 |
| 8902 | M | RSV 276 | DS-Cav1/B3TMCT | 3.7 | 14.4 |
| 8952 | M | RSV 276 | DS-Cav1/B3TMCT | 4.7 | 15.5 |
a
M, male; F, female.
b
Sera were collected 35 days before boosting and were analyzed with the RSV PRN assay with added complement. Values are for individual animals. The mean pre-boosting serum RSV-neutralizing titers were 6 log2 PRNT for the first two groups and 6.1 log2 PRNT for the third group.
c
Sera were collected 2 weeks after boosting and were analyzed with the RSV PRN assay with added complement. Values are for individual animals.